Azorin Jean-Michel, Murteira Susana, Hansen Karina, Toumi Mondher
Department of Psychiatry, CHU Sainte Marguerite, Marseilles, France.
BMC Psychiatry. 2008 Mar 14;8:16. doi: 10.1186/1471-244X-8-16.
Use of the atypical antipsychotic sertindole was suspended for four years due to safety concerns. During the suspension, the regulatory authorities required further studies, including this one, to be conducted. The purpose of this study was to determine if a subset of patients with psychotic illness exists which particularly benefits from sertindole treatment after failure of other antipsychotic drugs, including atypical antipsychotics.
This was a retrospective single-arm observational crossover study of 344 patients, who served as their own controls. Patients mainly from the Sertindole Safety Study who had shown good response to sertindole, and who had followed up to four alternating six month periods of treatment with sertindole and other antipsychotics, were included. (In Period 1 patients took non-sertindole treatment, in Period 2, sertindole was taken, in Period 3, patients reverted to non-sertindole treatment, and in Period 4, sertindole was taken again.) Patient records for each period of treatment were assessed for objective data: number and duration of hospitalizations due to worsening of psychotic symptoms; the amount of self-harming behaviour; indicators of social status. Retrospective evaluation of changes in clinical symptoms from the patients' records was also conducted. Dates and reasons for stopping and/or switching medication were also recorded.
There was improvement in all objective measured parameters during the periods of sertindole treatment. In particular, the average number of hospitalizations per year due to worsening of psychotic symptoms was reduced in the following way in the group studied over four treatment periods: Period 1 (non-sertindole treatment) 3.4; Period 2 (sertindole treatment) 1.0; Period 3 (non-sertindole treatment) 2.0; Period 4 (sertindole treatment) 1.8. The duration of hospitalizations also decreased significantly during the periods of sertindole treatment. Results showed that patients improved in objective social parameters when switched to sertindole treatment; assessment of the patients' affective lives showed a significant increase in the number of patients having a stable relationship during sertindole treatment; and assessment of the number of patients employed showed an increase after the first and second switch to sertindole treatment (from Period 1 to Period 2 and from Period 3 to Period 4, respectively). Adverse events and lack of efficacy were the main reasons for switching to sertindole.
A group of patients benefited from sertindole after other antipsychotic treatments, including that with atypical antipsychotics, had failed. Further studies are needed to investigate if there is a specific patient profile that corresponds to these responders.
由于安全问题,非典型抗精神病药物舍吲哚的使用被暂停了四年。在暂停期间,监管机构要求进行包括本研究在内的进一步研究。本研究的目的是确定是否存在一组精神病患者,他们在包括非典型抗精神病药物在内的其他抗精神病药物治疗失败后,特别受益于舍吲哚治疗。
这是一项对344名患者进行的回顾性单臂观察性交叉研究,患者自身作为对照。主要纳入来自舍吲哚安全性研究的患者,这些患者对舍吲哚显示出良好反应,并接受了四个交替的为期六个月的舍吲哚治疗期和其他抗精神病药物治疗期的随访。(在第1期患者接受非舍吲哚治疗,第2期服用舍吲哚,第3期患者恢复非舍吲哚治疗,第4期再次服用舍吲哚。)对每个治疗期的患者记录进行客观数据评估:因精神病症状恶化导致的住院次数和住院时长;自伤行为的数量;社会状况指标。还对患者记录中的临床症状变化进行回顾性评估。记录停药和/或换药的日期及原因。
在舍吲哚治疗期间,所有客观测量参数均有改善。特别是,在四个治疗期研究的组中,因精神病症状恶化导致的每年平均住院次数以下列方式减少:第1期(非舍吲哚治疗)3.4次;第2期(舍吲哚治疗)1.0次;第3期(非舍吲哚治疗)2.0次;第4期(舍吲哚治疗)1.8次。在舍吲哚治疗期间住院时长也显著减少。结果表明,改用舍吲哚治疗时患者的客观社会参数有所改善;对患者情感生活的评估显示,在舍吲哚治疗期间拥有稳定关系的患者数量显著增加;对就业患者数量的评估显示,在首次和第二次改用舍吲哚治疗后(分别从第1期到第2期以及从第3期到第4期)有所增加。不良事件和缺乏疗效是改用舍吲哚的主要原因。
一组患者在包括非典型抗精神病药物治疗在内的其他抗精神病治疗失败后,从舍吲哚治疗中获益。需要进一步研究以调查是否存在与这些有反应者相对应的特定患者特征。